HER2 overexpression in breast cancer (BC) is strictly connected to the underlying presence of ERBB2 amplification [1] to which they become addicted [2], providing the basis of successful treatment of these tumors with traditional and novel anti-HER2 agents [1]. The gene discussed is ERBB2; the disease is breast carcinoma.